Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents01:17

Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents

Diarrhea, a condition marked by frequent loose or watery bowel movements, can be triggered by multiple factors such as viral or bacterial infections, food intolerances, anxiety, medications, and digestive disorders. Symptoms may include abdominal pain, bloating, nausea, and cramping. Severe or prolonged diarrhea can lead to complications like electrolyte imbalances, malnutrition, and dehydration if left untreated.
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation. 
Drugs Affecting GI Tract Motility: Other Laxatives01:20

Drugs Affecting GI Tract Motility: Other Laxatives

Laxatives are primarily used to alleviate constipation, a common gastrointestinal disorder characterized by infrequent bowel movements and difficulty passing stools. They work by various mechanisms to increase the volume or frequency of bowel movements. The primary modes of action of laxatives include increasing stool bulk, softening the stool, stimulating intestinal motility, and osmotically drawing water into the intestines.
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Frailty as a predictor of adverse in-hospital outcomes in older patients with Takotsubo cardiomyopathy.

Journal of geriatric cardiology : JGC·2026
Same author

Opioid use disorder and clinical outcomes following percutaneous coronary intervention for acute coronary syndromes.

Journal of thrombosis and thrombolysis·2026
Same author

Predicting Risk of Cardiovascular Disease Events (PREVENT) Versus Pooled Cohort Equations for 10-Year Atherosclerotic Cardiovascular Disease Risk Prediction: A Meta-Analysis.

Critical pathways in cardiology·2026
Same author

Trends and Disparities in Mortality due to Pulmonary Embolism Among Adults With Atrial Fibrillation From 1999 to 2020: Insights From the CDCWONDER Database.

Journal of arrhythmia·2026
Same author

Impact of comorbid mental disorders on in‑hospital mortality and complications after ST‑segment elevation myocardial infarction.

Future cardiology·2026
Same author

Dyspnea and a Fistula: A Case Report of an Unusual Cardiac Connection.

Case reports in medicine·2026
Same journal

GLP-1 Receptor Agonists and Age-related Macular Degeneration Risk in Diabetes or Non-diabetic Obesity: A Retrospective Cohort Study.

The American journal of medicine·2026
Same journal

Marijuana Use and Acute Myocardial Infarction: Mechanistic Insights, Clinical Implications, and Emerging Challenges.

The American journal of medicine·2026
Same journal

Cave Canem - Beware of the Dog.

The American journal of medicine·2026
Same journal

Risk Factors for 30-day Hospital Readmission After Hospital-at-Home Treatment of Acute Pyelonephritis.

The American journal of medicine·2026
Same journal

Mesenteric Panniculitis.

The American journal of medicine·2026
Same journal

Hypercalcemia and hyperferritinemia in a patient with Graves' disease disease.

The American journal of medicine·2026
See all related articles

Related Experiment Video

Updated: Jun 2, 2026

Multimodality Diagnosis of Mesenteric Ischemia
05:07

Multimodality Diagnosis of Mesenteric Ischemia

Published on: July 21, 2023

Illicit drug, ischemic bowel

Khaldoon Shaheen1, M Chadi Alraies, Houssam Marwany

  • 1Department of Medicine, Case Western Reserve University/St Vincent Charity Medical Center, Cleveland, Ohio, USA. khaldoon.shaheen@csauh.com

The American Journal of Medicine
|May 3, 2011
PubMed
Summary

No abstract available in PubMed .

More Related Videos

Murine Model of Intestinal Ischemia-reperfusion Injury
07:07

Murine Model of Intestinal Ischemia-reperfusion Injury

Published on: May 11, 2016

Rodent Model of Intestinal Ischemia-Reperfusion Injury via Occlusion of the Superior Mesenteric Artery
06:29

Rodent Model of Intestinal Ischemia-Reperfusion Injury via Occlusion of the Superior Mesenteric Artery

Published on: October 20, 2023

Related Experiment Videos

Last Updated: Jun 2, 2026

Multimodality Diagnosis of Mesenteric Ischemia
05:07

Multimodality Diagnosis of Mesenteric Ischemia

Published on: July 21, 2023

Murine Model of Intestinal Ischemia-reperfusion Injury
07:07

Murine Model of Intestinal Ischemia-reperfusion Injury

Published on: May 11, 2016

Rodent Model of Intestinal Ischemia-Reperfusion Injury via Occlusion of the Superior Mesenteric Artery
06:29

Rodent Model of Intestinal Ischemia-Reperfusion Injury via Occlusion of the Superior Mesenteric Artery

Published on: October 20, 2023